Indaptus Therapeutics, Inc. (NASDAQ:INDP) to Post Q1 2025 Earnings of ($0.38) Per Share, HC Wainwright Forecasts

Indaptus Therapeutics, Inc. (NASDAQ:INDP) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Indaptus Therapeutics in a report released on Monday, April 15th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn ($0.38) per share for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Indaptus Therapeutics’ current full-year earnings is ($1.73) per share. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS and FY2025 earnings at ($1.44) EPS.

Indaptus Therapeutics Trading Up 4.3 %

Shares of NASDAQ INDP opened at $2.73 on Tuesday. Indaptus Therapeutics has a 12 month low of $1.56 and a 12 month high of $4.08. The firm has a market capitalization of $23.31 million, a PE ratio of -1.48 and a beta of 1.28. The firm has a fifty day simple moving average of $2.11 and a two-hundred day simple moving average of $2.10.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings results on Wednesday, March 13th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in shares of Indaptus Therapeutics by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 256,265 shares of the company’s stock worth $451,000 after buying an additional 5,517 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Indaptus Therapeutics in the 2nd quarter worth about $51,000. State Street Corp purchased a new stake in shares of Indaptus Therapeutics in the 1st quarter worth about $78,000. Citadel Advisors LLC purchased a new stake in shares of Indaptus Therapeutics in the 4th quarter worth about $29,000. Finally, Northern Trust Corp purchased a new stake in shares of Indaptus Therapeutics in the 1st quarter worth about $41,000. 7.06% of the stock is currently owned by institutional investors.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial.